These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 32497490)

  • 1. Chasing the cabotegravir tail: implications for prevention.
    Scarsi KK
    Lancet HIV; 2020 Jul; 7(7):e451-e453. PubMed ID: 32497490
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-acting cabotegravir for prevention: hope versus reality.
    McCormack S; Boffito M
    Lancet HIV; 2017 Aug; 4(8):e322-e323. PubMed ID: 28546089
    [No Abstract]   [Full Text] [Related]  

  • 3. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabotegravir, a new option for PrEP.
    Kirby T
    Lancet Infect Dis; 2020 Jul; 20(7):781. PubMed ID: 32592669
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Smith RA; Wu VH; Zavala CG; Raugi DN; Ba S; Seydi M; Gottlieb GS;
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabotegravir Sodium.
    Am J Health Syst Pharm; 2021 May; 78(11):920-924. PubMed ID: 33821887
    [No Abstract]   [Full Text] [Related]  

  • 11. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
    Orkin C; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Overton ET; Girard PM; Oka S; Walmsley S; Bettacchi C; Brinson C; Philibert P; Lombaard J; St Clair M; Crauwels H; Ford SL; Patel P; Chounta V; D'Amico R; Vanveggel S; Dorey D; Cutrell A; Griffith S; Margolis DA; Williams PE; Parys W; Smith KY; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1124-1135. PubMed ID: 32130806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
    Murray M; Pulido F; Mills A; Ramgopal M; LeBlanc R; Jaeger H; Canon V; Dorey D; Griffith S; Mrus J; Spreen W; Margolis D
    HIV Res Clin Pract; 2019; 20(4-5):111-122. PubMed ID: 31533539
    [No Abstract]   [Full Text] [Related]  

  • 16. A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls.
    Shaik JSB; Ford SL; Lou Y; Zhang Z; Bakshi KK; Tenorio AR; Trezza C; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):664-673. PubMed ID: 30811880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants.
    Parasrampuria R; Ford SL; Lou Y; Fu C; Bakshi KK; Tenorio AR; Trezza C; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):674-681. PubMed ID: 30809978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects.
    Lou Y; Buchanan AM; Chen S; Ford SL; Gould E; Margolis D; Spreen WR; Patel P
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):509-516. PubMed ID: 27162089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis.
    Stellbrink HJ; Hoffmann C
    Curr Opin HIV AIDS; 2018 Jul; 13(4):334-340. PubMed ID: 29746267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.